AstraZeneca partners with MRC on drug discovery efforts

AstraZeneca has formed a new partnership with the UK's Medical Research Council (MRC) that aims to speed translation of discovery research into potential new therapies.

The deal will give researchers the chance to apply for unprecedented access to AstraZeneca's high-throughput screening drug discovery capabilities at the joint MRC/AstraZeneca Centre for Lead Discovery.

This includes access to the company's drug discovery robotics platform NiCoLA-B, as well as a high-quality, chemically-diverse collection of more than two million compounds.

With recent developments in robotics and technology meaning that facilities such as AstraZeneca's can now screen more than 300,000 compounds per day, it is expected that the collaboration will make the drug discovery process smarter, faster and cheaper.

Mark Wigglesworth, director of high-throughput screening at AstraZeneca, said: "AstraZeneca is committed to creating a truly innovative and collaborative research environment and this first-of-its-kind initiative will enable our teams to work side by side with world-leading MRC scientists."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.